Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03306420 · ClinicalTrials.gov registry record · Phase 1
First-in-Human Study of MS201408-0005A as Single Agent and in Combinations
A Phase 1 study, sponsored by EMD Serono Research & Development Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03306420 is a Phase 1 study that was terminated before completion, run by EMD Serono Research & Development Institute. The registered enrollment target is 15 participants.
The verdict
NCT03306420, a Phase 1 study, was terminated before completion, sponsored by EMD Serono Research & Development Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a Phase I, open-label study to determine the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD), and preliminary antitumor activity of MS201408-0005A as single agent (Part IA only) and in combination with MS201408-0005C or MS201408-0005B (Part IB, Part IC).
Interventions
- DRUG M4112
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-10-03 |
| Est. Completion | 2019-01-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03306420
The ClinicalTrials.gov registry entry for NCT03306420 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which M4112 is the first listed.
NCT03306420 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03306420 about?
NCT03306420 is a clinical study titled "First-in-Human Study of MS201408-0005A as Single Agent and in Combinations". This is a Phase I, open-label study to determine the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD), and preliminary antitumor activity of MS201408-0005A as single agent (Part IA only) and in combination with MS201408-0005C or MS201408-0005B (Part IB, Part IC).
What is the current status of trial NCT03306420?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2017-10-03. Estimated completion is 2019-01-14.
What interventions are being tested in trial NCT03306420?
The interventions under investigation include: M4112 (DRUG).
Who is sponsoring clinical trial NCT03306420?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.